Table 1.
Patient and tumor characteristics
| Variable | Interval ≤ 9 wk (group A, n = 139) | Interval > 9 wk (group B, n = 92) | P value |
| Sex, n (%) | 0.279 | ||
| Male | 100 (71.9) | 60 (65.2) | |
| Female | 39 (28.1) | 32 (34.8) | |
| Age (year, mean ± SD) | 58.6 ± 10.6 | 58.9 ± 11.7 | 0.645 |
| ASA, n (%) | 0.280 | ||
| 1 | 4 (2.9) | 3 (3.3) | |
| 2 | 111 (79.9) | 67 (72.8) | |
| 3 | 24 (17.2) | 22 (23.9) | |
| BMI (kg/m2 , mean ± SD) | 23.8 ± 3.4 | 24.4 ± 2.9 | 0.063 |
| cT, n (%) | 0.318 | ||
| 2 | 2 (1.4) | 0 (0) | |
| 3 | 110 (79.1) | 70 (76) | |
| 4 | 27 (19.4) | 22 (24) | |
| cN, n (%) | 0.355 | ||
| 0 | 40 (28.8) | 22 (23.9) | |
| 1 | 71 (51.1) | 48 (52.2) | |
| 2 | 28 (20.1) | 22 (23.9) | |
| Preoperative carcinoembryonic antigen (μg/L, mean ± SD) | 5.4 ± 10.8 | 5.8 ± 13.7 | 0.182 |
| Preoperative concurrent chemotherapy regimen, n (%) | 0.712 | ||
| Capecitabine + oxaliplatin | 32 (23) | 29 (31.5) | |
| Capecitabine oral | 87 (62.6) | 58 (63) | |
| Oxaliplatin union | 21 (15.1) | 5 (5.4) |
BMI: Body mass index; ASA: American Society of Anesthesiologists.